News Center

TruGolf (NASDAQ: TRUG) provided a summary of recent corporate developments as it advances its previously announced acquisition of Polymath Research Inc. (“Polymath”), a developer of institutional-grade infrastructure for regulated digital securities and tokenized real-world assets. TruGolf entered into an agreement Aug. 18 to acquire Polymath, including its tokenization platform and purpose-built Layer-1 blockchain, Polymesh. Recent […]

Greenland Mines (NASDAQ: GRML) announced that its common shares are now listed and trading on the Frankfurt Stock Exchange under the symbol HK6, providing European investors with an additional venue to access the company shares and complementing its principal Nasdaq listing. No new shares are being issued in connection with the Frankfurt listing. The listing […]

Nano-X Imaging Ltd. (NASDAQ: NNOX) is approaching that problem from a different direction. Rather than building another high-end system for major hospitals, Nanox is assembling an integrated platform intended to extend medical imaging into outpatient facilities, clinics and other settings where conventional advanced imaging infrastructure is difficult to justify. Nanox.ARC: Expanding Access to 3D Imaging […]

First smartphone to run HarmonyOS 7 and include chip design breakthrough LogicFoldingSHENZHEN, CHINA – Media OutReach Newswire – 28 September 2026 – Huawei released the HUAWEI Mate XT 2 | ULTIMATE DESIGN trifold smartphone on September 7. The phone is the first to run HarmonyOS 7, and is the slimmest and largest foldable smartphone in the industry. The Mate XT 2's Kirin 9050 chip also includes a major breakthrough in semiconductor design. As the first smartphone to feature the LogicFolding Tau (τ) Chip, the Mate XT 2 marks the chip's official entry into mass commercialization. World-class engineering and design The device is proving popular with consumers due to its foldable wing-like form, which means it can be opened up, transforming the phone into a tablet. The engineering to make this possible is unprecedented. The glass screen must be tough enough to withstand daily use, whilst being able to fold thousands of times. The hinge to allow the screen to fold is the first of its kind. Once open, the handset is just 3.5mm thick. However, the screen is not the only remarkable folding technology in the device. The first chip with semiconductor design breakthrough, LogicFolding The Mate XT 2 Ultimate Design includes a major breakthrough in semiconductor design. The phone is the first to use Huawei's LogicFolding Tau chip Kirin 9050 Pro. Designed by engineers in Huawei's HiSilicon team, the chip offers a solution to the problem of geometric scaling. With Moore's law (the historical observation that the number of transistors on a microchip doubles approximately every two years) believed to be reaching its physical limit, making chips smaller is becoming more challenging and costly. For Huawei, faced with external restrictions, the need to find a solution came sooner than expected. In May this year, He Tingbo, President of Huawei's HiSilicon division, unveiled a new way of designing and making chips, alongside a new law to measure their performance, the τ (Tau) Scaling Law. The work led to Ms He being recently named one of the world's leading AI innovators by Time Magazine. The point of shrinking transistors was never the smallness itself, it's what the smallness delivered. Shoppers looking to buy the latest smartphone don't care if the chips inside have 7, 5 or even 2-nanometer nodes, they care about the performance of the device in their hands. What matters to consumers is the time it takes for a task to be completed, a video to be shared or a game to load. The performance of the chip should be measured in the same way: by time, not size. This is why Huawei proposed τ (Tau) Scaling Law as an alternative to Moore's Law. Breaking through barriers to improve performance The Kirin 9050 Pro uses 3D integration to boost performance. Traditional chip advancement focussed on packing more and more transistors into a linear plain by making each one smaller. LogicFolding uses 3D integration to reduce the distance between transistors by stacking them on top of one another, increasing the number of transistors whilst reducing the distance between them. In fact, in the Kirin 9050 Pro transistor density has risen from approximately 155 to 238 million transistors per square millimetre. That's an equivalent increase to what was achieved in the previous three years using geometric shrinking. It was thought that stacking active transistors on top of each other and sealing them inside a solid mobile device would present an engineering challenge. Power turns into heat, which in a confined space would raise the temperature and ultimately break the device. The key to the solution came in recognising that integrated chips have both transistors and circuits. As He Tingbo explains in her IEEE article, Huawei's τ Chip Was Supposed to Melt?, the inner workings of a chip can be compared to an office worker's day of work. Many office workers will use more energy on their commute to and from the office than they do at their desk because they are moving around more on the road. The 'work' part of their day is not the most energy intensive part as they are often seated at their desk. The same is true for chips. The most energy intensive part of the process is the 'commute', moving data from point A to point B, not processing it. Integrated circuits use power in two main ways. The first is switching, flipping a transistor gate to change a bit from 0 to 1 and back. The second is the transmission of that data, moving the bits from one part of the chip to another. This is important in mobile phones where a lot of performance requirements are asked of a single chip. Equally, however, in a large AI cluster 80% of the energy is used in the moving the data, not processing it. In both cases, LogicFolding reduces the space between transistors which in turn reduces the power used. The previous assumption that packing transistors on top of one another would increase the heat turned out to be false. In fact, even with a higher transistor density per millimetre, LogicFolding chips run cooler per unit of work. The result is Huawei's most powerful smartphone ever. The first phone to run HarmonyOS 7 The Mate XT 2 is the first smartphone to run HarmonyOS 7. Forty-two percent more powerful than the previous generation, it remains the slimmest and largest foldable display in the industry when open. The cover screen spans 6.5 inches, boosting the screen-to-body ratio from 86.4% to 92.8%. Enhanced with 70% better anti-reflection, the screen exhibits a deeper, cleaner black when off, and pure, crystal-clear transparency when lit. The Huawei Mate XT 2 also introduces the world-first Smart Shield Privacy Screen on a foldable screen. Two independent pixel sets co-exist within the 10.2-inch display at a micro-pitch of just 9 μm. When Privacy Mode is activated, the screen seamlessly switches from a wide viewing angle to a narrow one while maintaining identical resolution and clarity, protecting your privacy in public spaces without compromising your view. Industry first ECG analysis Health tech is increasing important to consumers, and so the Mate XT 2 is the industry's first smartphone to introduce ECG analysis. Capitalising on the innovative tri-fold form factor, users can simply hold both side frames with both hands while unfolded to capture a 30-second ECG signal. Paired with the medically certified analysis software, it generates detailed ECG reports to help identify Sinus Rhythm, Atrial Fibrillation, and Premature Beats. The launch of the Mate XT 2 marks a significant moment in Huawei's journey. The company's R&D has delivered industry leading, and industry changing innovation. More than half of Huawei's employees work in R&D. That's over 100,000 people. The company currently holds 160,000 active patents worldwide. In the first half of 2026 alone, Huawei's R&D investment was over RMB 121 billion, accounting for 25.94% of revenue, up 25.2% year on year. The HUAWEI Mate XT 2 | ULTIMATE DESIGN starts at RMB 19,999 and is now available for purchase, along with a stylus set, following its official sales launch at 10:08 on September 12th. Hashtag: #HuaweiThe issuer is solely responsible for the content of this announcement.

Launch of new products, market expansion and AI-enabled capabilities mark the next stage of growth for a global healthcare technology company anchored by six decades of trusted medical data and expertise.SINGAPORE – Media OutReach Newswire – 28 September 2026 – MIMS Group, an Asia-Pacific provider of medicines information, clinical decision support, medical communications and marketing services, is accelerating product innovation and international growth as it transforms its long-standing healthcare data, content and market expertise into new technology platforms, customer applications and services. Following the appointment of Sohil Goswami as Group CEO in January 2026, MIMS has reshaped its businesses and leadership structure to support its next phase of growth. The company is now ready to harness its data, technology and healthcare relationships to create scalable products and new business models across markets. Clinical Decision Support expands across products and markets MIMS recently launched MIMS Pulse, its next-generation Clinical Decision Support platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment and integration capabilities to support safer and more efficient clinical workflows. Alongside MIMS Pulse, the company is scaling eMIMS Plus, a platform that brings MIMS' trusted medicines information into a modern digital experience designed to achieve quality use of medicine. Conceived and first launched in Australia under Goswami's guidance in his previous role leading the CDS Business, eMIMS Plus is now available in India and Malaysia with plans to expand across Southeast Asia, introduce new clinical modules, as well as extend into new healthcare categories through Drugs4Dent. MIMS is developing its global CDS offering, building on MIMS Pulse and eMIMS Plus to take its clinical data and technology capabilities into new markets and customer environments. Medical Marketing business transforms for global growth MIMS' Medical Communications business is expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organisations. The business continues to develop digital events, AI-enabled content capabilities and new customer engagement models. MIMS is exploring more connected, intelligence-led services – helping healthcare and life sciences organisations better understand their markets, engage healthcare professionals and make more informed decisions. This work represents an important step beyond MIMS' traditional information and communications models, applying its content data and market reach to new technology-enabled services. Goswami said: "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services. We have been reshaping the business – bringing our capabilities together, strengthening our technology and building new ways to serve customers across markets. Our opportunity is to turn trusted medical data, deep healthcare relationships and market knowledge into the next generation of products, platforms and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve." The developments form part of a broader evolution across MIMS as the company builds on its established strengths while extending its products, capabilities and reach into new areas of healthcare. Hashtag: #MIMS #MIMSPulse #eMIMSPlus #clinicaldecisionsupport #medicalmarketing #AIinhealth #digitalhealth #healthcareinnovation #healthtech #HCP The issuer is solely responsible for the content of this announcement.About MIMS: Empowering Healthcare Communities to Improve Patient OutcomesMIMS is Asia's largest multi-channel provider of drug information, medical communications, events management, marketing, and recruitment services. Established in 1963, our work empowers healthcare professionals to improve patient outcomes by facilitating knowledge exchange and better decision-making. Today, MIMS is present in 17 markets globally with over two million healthcare professional subscribers to our drug & resource portal, digital and print publications. Combining healthcare communications expertise with our established networks and presence in the Asian healthcare community, we enable clients to engage their stakeholders in meaningful dialogue through a range of medical and marketing communications services. We facilitate long-term placement of nurses, pharmacists and doctors across the globe to match the demands of healthcare institutions looking for high-calibre practitioners. MIMS has offices in the following global markets: Singapore (headquarters), Australia, China, Germany, Hong Kong SAR, Indonesia, India, Ireland, Japan, Korea, Malaysia, New Zealand, Philippines, Taiwan, Thailand, UAE, Vietnam Learn more at https://corporate.mims.com/ or follow https://www.linkedin.com/company/mims-pte-ltd/

A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational […]

Every new AI model announced this year needs somewhere to run, and increasingly, that somewhere does not yet exist. Azio AI Holdings (NASDAQ: AZIO) is committed to closing that gap, building the data centers, GPU systems and power infrastructure that turn AI ambition into working compute. Once upon a time, the bottleneck holding back the […]

Greenland Mines (NASDAQ: GRML) raised more than $42 million from existing investors through a registered direct offering of common stock and pre-funded warrants and the exercise of previously issued private warrants. The company said the financing provides the capital it believes is required to execute planned exploration and development programs and achieve targeted 2027 milestones […]

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. Xlife Sciences AG (SIX: XLS) said VERAXA secured a financing base to support its next development steps […]

Greenland Mines (NASDAQ: GRML) applauded the formal signing at the United Nations General Assembly of a new security agreement among the United States, the Kingdom of Denmark and Greenland. The company said the agreement formalizes the framework announced Friday and marks a milestone in strengthening long-term Arctic and North Atlantic security while underscoring Greenland growing […]